Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM)

Sophia Adamia, PhD, Shruti Bhatt, PhD, Yu-Tzu Tai, PhD, Kenneth Wen, Catherine A Nicholas, Marissa S Pioso, Ivane Abiatari, MD, Anthony G. Letai, MD PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-142596

Published: 2020

Journal Articles

CCR2 Expression Signature Can Classify and Predict Outcome in a Subpopulation of Chronic Lymphocytic Leukemia (CLL) Patients

Salma Parvin, PhD, Aditi Aryal, BA, Matthew S. Davids, MD, Anthony G. Letai, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-141642

Published: 2020

Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Marina Konopleva, MD PhD, Michael Thirman, MD, Keith W. Pratz, MD, Anthony G. Letai, MD PhD, Christian Recher, MD PhD, Vinod A. Pullarkat, MD, Hagop M. Kantarjian, MD, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Catherine Miller, PharmD, Courtney D. Dinardo, MDMSc, Andrew H. Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134100

Published: 2020

Journal Articles

Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Anthony G. Letai, MD PhD, Jeremy M. Stewart, BA, Michael McGinnis, Francis Brown, JD, Geoffrey Fell, Yael Flammand, Marina Konopleva, MD PhD, Jacqueline S. Garcia, MD, Marlise R Luskin, MDMS

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-140646

Published: 2020

Journal Articles

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Blood (2019) 134 (Supplement_1): 258.

https://doi.org/10.1182/blood-2019-126172

Published: 2019

Journal Articles

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

Keith W. Pratz, MD, Courtney D. DiNardo, MD MSc, Martha L. Arellano, MD, Anthony G. Letai, MD PhD, Michael Thirman, MD, Vinod A. Pullarkat, MD, Gail J. Roboz, MD, Pamela S. Becker, MD PhD, Wan-Jen Hong, MD, Qi Jiang, John Hayslip, MD MSCR, Jalaja Potluri, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 264.

https://doi.org/10.1182/blood-2019-127251

Published: 2019

Journal Articles

MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers

Blood (2019) 134 (Supplement_1): 1284.

https://doi.org/10.1182/blood-2019-131336

Published: 2019

Journal Articles

Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL

Valeriya Dimitrova, Huiyoung Yun, PhD, Sayalee Potdar, Alexandria Nicole Van Scoyk, BS, Shruti Bhatt, PhD, Praveen Anand, PhD, Monica S. Nair, Jake A. Kloeber, Antonis Kokkalis, PhD MSc, Julia Frede, PhD MPhil, Johannes M. Waldschmidt, MD, Anthony G. Letai, MD PhD, David M. Weinstock, MD, Jon C. Aster, MD PhD, Jens G. Lohr, MD PhD, Birgit Knoechel, MD PhD

Blood (2019) 134 (Supplement_1): 3948.

https://doi.org/10.1182/blood-2019-131148

Published: 2019

Journal Articles

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Caroline Kokulis, Jeremy M. Stewart, BA, Michael McGinnis, Lillian Werner, MS, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Marlise Luskin, MDMS

Blood (2019) 134 (Supplement_1): 3908.

https://doi.org/10.1182/blood-2019-124966

Published: 2019

Journal Articles

A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia

Nitin Jain, MD, Kristen E. Stevenson, MS, Eric S. Winer, MD, Jacqueline S Garcia, MD, Richard M. Stone, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Jeremy M. Stewart, BA, Dean R Legg, BA, Hagop M. Kantarjian, MD, Donna S Neuberg, ScD, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Daniel J. DeAngelo, MD

Blood (2019) 134 (Supplement_1): 3867.

https://doi.org/10.1182/blood-2019-129988

Published: 2019

Journal Articles

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Shanye Yin, PhD, Salma Parvin, PhD, Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Heather Joyal, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Matthew S. Davids, MD, Ruben D. Carrasco, MD PhD, Anthony G. Letai, MD PhD, Catherine J. Wu, MD

Blood (2019) 134 (Supplement_1): 4281.

https://doi.org/10.1182/blood-2019-127293

Published: 2019

Journal Articles

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

Blood (2014) 124 (21): 3713.

https://doi.org/10.1182/blood.V124.21.3713.3713

Published: 2014

Journal Articles

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Todd Rosenblat, MD, Mark L. Heaney, MD PhD, Joseph G Jurcic, MD, Azra Raza, MD, John G. Mears, MD, Ruth Santos, BS, Diana Carrillo, BS, David Shum, MS, Jacquelyn Gonzales, BSN, RN, Kevin Zikaras, BS, Martin Santos, BS, Rong Zhang, MS, Glorymar Ibanezs, MS, Leah Hogdal, BA, Jennifer Crombie, MD, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony G. Letai, MD PhD, Mark G. Frattini, MD PhD

Blood (2014) 124 (21): 974.

https://doi.org/10.1182/blood.V124.21.974.974

Published: 2014

Journal Articles

BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics

Cyrille Touzeau, MD, Jeremy Ryan, SM, Philippe Moreau, MD, Triona Ni Chonghaile, PhD, Steven Le Gouill, Paul G. Richardson, Kenneth C. Anderson, Martine Amiot, PhD, Anthony G. Letai, MD PhD

Blood (2014) 124 (21): 417.

https://doi.org/10.1182/blood.V124.21.417.417

Published: 2014

Journal Articles

Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2 Expression in CD4 Memory Regulatory T Cells

Kazuyuki Murase, MD PhD, Haesook T. Kim, PhD, Masahiro Hirakawa, MD PhD, Tiago Reis Matos, MD, Yutaka Kawano, MD PhD, Jeremy Ryan, SM, Ken-Ichi Matsuoka, MDPhD, John Koreth, MBBS, DPhil, Robert J Soiffer, MD, Anthony G. Letai, MD PhD, Junji Kato, MD PhD, Jerome Ritz, MD

Blood (2014) 124 (21): 1414.

https://doi.org/10.1182/blood.V124.21.1414.1414

Published: 2014

Journal Articles

A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

Blood (2014) 124 (21): 118.

https://doi.org/10.1182/blood.V124.21.118.118

Published: 2014

Journal Articles

Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia

Matthew S. Davids, MD, Jing Deng, PhD, Jeremy Ryan, SM, Stacey M. Fernandes, Jennifer R. Brown, Anthony G. Letai, MD PhD

Blood (2014) 124 (21): 1940.

https://doi.org/10.1182/blood.V124.21.1940.1940

Published: 2014

Journal Articles

Alterations In Mitochondrial Priming May Be a Mechanism For Acquired Resistance To Therapy In Diffuse Large B-Cell Lymphoma

Elizabeth Brem, MD, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD, Scott Rodig, M.D., Ph.D., Anthony G. Letai, MD, PhD

Blood (2013) 122 (21): 1764.

https://doi.org/10.1182/blood.V122.21.1764.1764

Published: 2013

Journal Articles

Differential Effects of TCR Stimulation and IL-2 On Apoptotic Pathways in CD4 Regulatory T Cells Compared to Conventional CD4 T Cells and CD8 T Cells

Kazuyuki Murase, MD, PhD, Yutaka Kawano, MD, PhD, Jeremy Ryan, Ken-ichi Matsuoka, MD, PhD, Gregory Bascug, BS, Sean McDonough, MS, Robert W Smith, BS, Suzan Lazo-Kallanian, John Daley, PhD, Matthew S. Davids, MD, Anthony G. Letai, MD, PhD, Jerome Ritz, MD

Blood (2012) 120 (21): 3280.

https://doi.org/10.1182/blood.V120.21.3280.3280

Published: 2012

Journal Articles

Apoptotic Pathways of Human Regulatory T Cells in Chronic Graft Versus Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Kazuyuki Murase, MD, PhD, Yutaka Kawano, MD, PhD, Jeremy Ryan, Ken-ichi Matsuoka, MD, PhD, Gregory Bascug, BS, Sean McDonough, MS, Robert W Smith, BS, Suzan Lazo-Kallanian, John Daley, PhD, John Koreth, MBBS, DPhil, Robert J. Soiffer, MD, Anthony G. Letai, MD, PhD, Jerome Ritz, MD

Blood (2012) 120 (21): 225.

https://doi.org/10.1182/blood.V120.21.225.225

Published: 2012

NARROW

Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM)

CCR2 Expression Signature Can Classify and Predict Outcome in a Subpopulation of Chronic Lymphocytic Leukemia (CLL) Patients

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML)

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers

Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics

Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2 Expression in CD4 Memory Regulatory T Cells

A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia

Alterations In Mitochondrial Priming May Be a Mechanism For Acquired Resistance To Therapy In Diffuse Large B-Cell Lymphoma

Differential Effects of TCR Stimulation and IL-2 On Apoptotic Pathways in CD4 Regulatory T Cells Compared to Conventional CD4 T Cells and CD8 T Cells

Apoptotic Pathways of Human Regulatory T Cells in Chronic Graft Versus Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only